Taysha Gene Therapies Stock Buy Hold or Sell Recommendation
| TSHA Stock | USD 3.24 0.24 8.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Taysha Gene Therapies is 'Sell'. Macroaxis provides Taysha Gene buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TSHA positions.
Check out Taysha Gene Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Taysha and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Taysha Gene Therapies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Taysha |
Execute Taysha Gene Buy or Sell Advice
The Taysha recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Taysha Gene Therapies. Macroaxis does not own or have any residual interests in Taysha Gene Therapies or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Taysha Gene's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | OK | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Taysha Gene Trading Alerts and Improvement Suggestions
| Taysha Gene is way too risky over 90 days horizon | |
| Taysha Gene appears to be risky and price may revert if volatility continues | |
| Taysha Gene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 15.45 M. Net Loss for the year was (111.57 M) with profit before overhead, payroll, taxes, and interest of 2.5 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (73.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: 104,535 Shares in Terns Pharmaceuticals, Inc. Purchased by Quest Partners LLC - MarketBeat |
Taysha Gene Returns Distribution Density
The distribution of Taysha Gene's historical returns is an attempt to chart the uncertainty of Taysha Gene's future price movements. The chart of the probability distribution of Taysha Gene daily returns describes the distribution of returns around its average expected value. We use Taysha Gene Therapies price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Taysha Gene returns is essential to provide solid investment advice for Taysha Gene.
| Mean Return | 0.94 | Value At Risk | -9.25 | Potential Upside | 12.25 | Standard Deviation | 7.94 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Taysha Gene historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Taysha Stock Institutional Investors
| Shares | Geode Capital Management, Llc | 2024-09-30 | 3.6 M | State Street Corp | 2024-09-30 | 3.5 M | Polar Capital Holdings Plc | 2024-09-30 | 3 M | Jpmorgan Chase & Co | 2024-09-30 | 3 M | Citadel Advisors Llc | 2024-09-30 | 2.9 M | Deutsche Bank Ag | 2024-06-30 | 2.5 M | Ghost Tree Capital, Llc | 2024-09-30 | 2.1 M | Longwood Capital Partners Llc | 2024-09-30 | 2.1 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 18.7 M | Venbio Select Advisor Llc | 2024-09-30 | 18.6 M |
Taysha Gene Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Taysha Gene or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Taysha Gene's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Taysha stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.64 | |
β | Beta against Dow Jones | 2.25 | |
σ | Overall volatility | 7.97 | |
Ir | Information ratio | 0.10 |
Taysha Gene Volatility Alert
Taysha Gene Therapies is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Taysha Gene's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Taysha Gene's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Taysha Gene Fundamentals Vs Peers
Comparing Taysha Gene's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Taysha Gene's direct or indirect competition across all of the common fundamentals between Taysha Gene and the related equities. This way, we can detect undervalued stocks with similar characteristics as Taysha Gene or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Taysha Gene's fundamental indicators could also be used in its relative valuation, which is a method of valuing Taysha Gene by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Taysha Gene to competition |
| Fundamentals | Taysha Gene | Peer Average |
| Return On Equity | -1.15 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Profit Margin | (2.30) % | (1.27) % |
| Operating Margin | (11.78) % | (5.51) % |
| Current Valuation | 568.87 M | 16.62 B |
| Shares Outstanding | 204.94 M | 571.82 M |
| Shares Owned By Insiders | 17.53 % | 10.09 % |
| Shares Owned By Institutions | 77.45 % | 39.21 % |
| Number Of Shares Shorted | 15.75 M | 4.71 M |
| Price To Book | 7.48 X | 9.51 X |
| Price To Sales | 66.97 X | 11.42 X |
| Revenue | 15.45 M | 9.43 B |
| Gross Profit | 2.5 M | 27.38 B |
| EBITDA | (105.2 M) | 3.9 B |
| Net Income | (111.57 M) | 570.98 M |
| Cash And Equivalents | 66.24 M | 2.7 B |
| Cash Per Share | 1.61 X | 5.01 X |
| Total Debt | 61.11 M | 5.32 B |
| Debt To Equity | 1.93 % | 48.70 % |
| Current Ratio | 1.79 X | 2.16 X |
| Book Value Per Share | 0.33 X | 1.93 K |
| Cash Flow From Operations | (73.02 M) | 971.22 M |
| Short Ratio | 3.05 X | 4.00 X |
| Earnings Per Share | 0.63 X | 3.12 X |
| Target Price | 6.59 | |
| Number Of Employees | 52 | 18.84 K |
| Beta | 0.41 | -0.15 |
| Market Capitalization | 664.02 M | 19.03 B |
| Total Asset | 172.73 M | 29.47 B |
| Retained Earnings | (513.01 M) | 9.33 B |
| Working Capital | 113.11 M | 1.48 B |
| Net Asset | 172.73 M |
Note: Acquisition by Nagendran Sukumar of 790093 shares of Taysha Gene subject to Rule 16b-3 [view details]
Taysha Gene Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Taysha . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Taysha Gene Buy or Sell Advice
When is the right time to buy or sell Taysha Gene Therapies? Buying financial instruments such as Taysha Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Taysha Gene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Wholesale Thematic Idea Now
Wholesale
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Wholesale theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wholesale Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Taysha Gene Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share 0.042 | Quarterly Revenue Growth (0.62) | Return On Assets (0.27) | Return On Equity (1.15) |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.